| Characteristics |
Group A |
Group E |
P |
GroupB |
GroupC |
GroupD |
Group F |
P |
| Number (%) |
508(35.8) |
429(34.2) |
NS |
370 |
345 |
197* |
- |
<0.05* |
| 912 (64.2)(B+C+D) |
825(65.8) |
NS |
| Mean age at the end of the study |
40.5±5.3 |
42.7±4.2 |
NS |
41.7±6.5 |
42.5±5.2 |
NS |
| Female (%) |
248 (17.5) |
233(18.7) |
NS |
453(31.9) |
435(34.7) |
NS |
| Monosensitized (%) |
317(26.7) |
298 |
NS |
489 |
385 |
- |
| Total IgE (U/l) ± SD |
145±87 |
195±33 |
NS |
206±76 |
231±54 |
NS |
| Mean duration of the disease (±SD) at the start of treatment (SIT) |
4.9±3.1 |
- |
- |
3.3±2.8 |
- |
- |
| Mean duration of SIT (±SD) in years |
5.2±2.2 |
- |
- |
3.8±1.4 |
- |
|
| Mean cumulative SIT dose in TU (±SD) |
36667*±8222 |
- |
- |
20130*±2341 |
16310*±3850 |
35920*±6292 |
- |
- |
|
| NS: Not Significant; TU: Therapeutic Units,* -the cumulative doses are not comparable due to different types of SIT (natured HDM-mixture and chemically modified allergens) |
| Table 1: The analyzed patient characteristics at the beginning of the observational period. |
